FDA recall record

Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 100 Tablets per carton recall — FDA D-0132-2025

Subpotent and Superpotent Drug

Class IIclassification
D-0132-2025official record ID
Dec 18, 2024report date

Recall record at a glance

Official recordD-0132-2025
CategoryDrug Recalls
ClassificationClass II
FDA record statusOngoing
Recalling firmMylan Institutional, Inc.
Report dateDec 18, 2024
Recall initiation dateNov 19, 2024
Quantity988 cartons
LocationRockford, IL, United States

Official product description

Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 42292-039-20

Why the product was recalled

Subpotent and Superpotent Drug

Distribution information

Nationwide in the USA.

How to read the classification

FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.